Scholarlink

<p>The emergence of biologics and Janus kinase inhibitors (JAKis) has revolutionized the management of immune-mediated skin diseases (IMSDs) through the selective inhibition of key mediators involved in the pathogenic process. In recent years, the enormous potential of these medications has prompted several therapeutic regulatory approvals, predominantly in the adult population. The application of biologics in the pediatric population is comparatively limited. This review provides an up-to-date summary and discussion of current and emerging biologics and JAKis used in the treatment of common pediatric IMSDs, encompassing regulatory approvals and recent trial data.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pediatric immune-mediated skin diseases: a review of advancements in biologics and JAK inhibitor treatments

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月13日

查看全文
  • Emadodin Darchini-Maragheh,
  • Anthony Moussa

摘要

The emergence of biologics and Janus kinase inhibitors (JAKis) has revolutionized the management of immune-mediated skin diseases (IMSDs) through the selective inhibition of key mediators involved in the pathogenic process. In recent years, the enormous potential of these medications has prompted several therapeutic regulatory approvals, predominantly in the adult population. The application of biologics in the pediatric population is comparatively limited. This review provides an up-to-date summary and discussion of current and emerging biologics and JAKis used in the treatment of common pediatric IMSDs, encompassing regulatory approvals and recent trial data.